Tuesday, January 8, 2019

LEPTOSPIROSIS



LEPTOSPIROSIS



BACKGROUND
  • Leptospirosis is a disease that is caused by spirochete bacteria in the genus Leptospira. There are 10 pathogenic species, and more than 250 pathogenic serovars.
  • While leptospirosis occurs worldwide, it is more common in tropical or sub-tropical climates.
  • It is estimated that more than 1 million cases occur worldwide annually, including almost 60,000 deaths.
  • In the United States, approximately 100–150 leptospirosis cases are reported annually. Puerto Rico reports the majority of leptospirosis cases, followed by Hawaii.
  • Outbreaks of leptospirosis tend to occur after heavy rainfall or flooding in endemic areas, especially areas with poor housing and sanitation conditions.



TRANSMISSION

  • Leptospires are spread by the urine of infected animals (rodents, dogs, livestock, pigs, horses, wildlife).
  • The bacteria can survive for weeks to months in urine-contaminated water and soil.
  • People can be infected through 
    • Direct contact with the urine or reproductive fluids from infected animals
    • Contact with urine-contaminated water (floodwater, rivers, streams, sewage) and wet soil
    • Ingestion of food or water contaminated by urine or urine-contaminated water.
  • Transmission occurs through mucous membranes, conjunctiva, and skin cuts or abrasions.
  • Human-to-human transmission is very rare but has been documented through sexual intercourse and breastfeeding. Transmission has also rarely occurred through animal bites.
  • High-risk activities can include wading, swimming, or boating in floodwater or freshwater (rivers, streams, lakes) that may be contaminated with animal urine. Some actions like prolonged immersion in, submerging head in, or swallowing contaminated water can particularly increase risk.
  • Other high risk activities can include direct contact with animals and activities that can lead to skin abrasions and water or soil exposure, such as clearing brush, trekking, and gardening.

CLINICAL FINDINGS

  • Incubation period is 2–30 days; most illnesses occur 5–14 days after exposure.
  • Most infections are thought to be asymptomatic.
  • Approximately 90% of clinical illnesses present as a nonspecific acute febrile illness, while approximately 10% progress to severe, potentially fatal illness with multi-organ dysfunction.
  • Illness may be biphasic, with the patient briefly recovering from mild illness, but then developing more severe illness. 
  • Symptoms can include fever, headache, myalgia (typically of the calves and lower back), conjunctival suffusion, nausea, vomiting, diarrhea, abdominal pain, cough, and sometimes a skin rash.
  • Severe symptoms can include jaundice, renal failure, hemorrhage (especially pulmonary), aseptic meningitis, cardiac arrhythmias, pulmonary insufficiency, and hemodynamic collapse. Combined renal and liver failure associated with leptospirosis is referred to as Weil’s disease.
  • Leptospirosis during pregnancy can cause fetal complications including fetal death or abortion.
  • The case fatality rate for leptospirosis is approximately 5%–15% among patients with severe illness. Among patients with severe pulmonary hemorrhagic syndrome, the case fatality rate can exceed 50%.

TREATMENT
  • Early treatment may decrease the severity and duration of disease. In patients with a high clinical suspicion of leptospirosis, initiating antibiotic treatment as soon as possible without waiting for laboratory results is recommended.
  • For patients with mild symptoms, doxycycline is the drug of choice (100 mg orally, twice daily), if not contraindicated. Other options include azithromycin (500 mg orally, once daily), ampicillin (500-750 mg orally, every 6 hours), amoxicillin (500 mg orally, every 6 hours).
  • For patients with severe disease, IV penicillin is the drug of choice (1.5 MU IV, every 6 hours), and ceftriaxone (1 g IV, every 24 hours) can be equally effective.

LABORATORY TESTING
  • Antibodies for leptospirosis develop between 3-10 days after symptom onset, thus any serologic test must be interpreted accordingly – negative serologic test results from samples collected in the first week of illness do not rule out disease, and serologic testing should be repeated on a convalescent sample collected 7-14 days after the first.
  •  In the acute phase of illness, leptospires are present in the blood (septicemia) for approximately the first 4–6 days of illness.
  • Leptospires may be shed intermittently in the urine after approximately the first week of illness onset. Due to the transience of leptospires in body fluids, a negative PCR test does not rule out leptospisosis.
  • It is best to submit as many specimen types as possible. Recommended specimens based on collection timing:
    • Acute illness (first week): whole blood and serum
    • Convalescent illness (after first week): serum +/- urine

PREVENTION

  • The first line of leptospirosis prevention is to avoid exposure.
  • Avoid wading, swimming, bathing, swallowing, or submersing head in potentially contaminated freshwater (rivers, streams) especially after periods of heavy rainfall or flooding.
  • Avoid contact with floodwater, and do not eat food contaminated with floodwater.
  • If exposure cannot be avoided, wear appropriate personal protective equipment (PPE) (rubber boots, waterproof coveralls/ clothing, gloves). Cover open wounds with waterproof dressings.
  • Treat unsafe or potentially contaminated drinking water by boiling or chemically treating.
  • Keep rodent populations (rats and mice) or other animal pests under control. Do not eat food that may have been exposed to rodents and possibly contaminated with their urine.
  • Some studies have shown that chemoprophylaxis with doxycycline might be effective in preventing clinical disease and could be considered for people at high risk and with short-term exposures.


Wednesday, January 2, 2019

EBOLA VIRUS DISEASE


EBOLA VIRUS DISEASE

  • Ebola Virus Disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a death rate of up to 90%.
  • The illness affects humans and nonhuman primates (monkeys, gorillas and chimpanzees)
  • The disease was first identified in 1976 in two simultaneous outbreaks, one in a village near the Ebola River in the Democratic Republic of Congo, and the other in a remote area of Sudan.


THE INFECTIOUS AGENT
  • A member of a family of RNA viruses called the Filoviridae
  • Subtypes
    • Ebola‐Zaire
    • Ebola‐Sudan
    • Ebola‐Ivory Coast
    • Ebola‐Bundibugyo
    • Ebola‐Reston.

TRANSMISSION

  • Ebola virus occurs by handling of infected chimpanzees, gorillas and forest antelopes, both dead and alive.
  • After the index case in an outbreak setting is infected, the virus can be transmitted in several ways.
    •  Direct contact with blood and /or secretions of an infected person.
    • Through contact with objects, such as needles, those have been contaminated with infected secretions.
    • Burial ceremonies
    • Nosocomial transmission 

INCUBATION PERIOD 


  • The incubation period for Ebola HF ranges from 2 to 21 days
SYMPTOMS


CLINICAL DIAGNOSIS

Diagnosing Ebola HF during the first few days is difficult because of nonspecific early symptoms, such as red eyes and skin rash. However, if a person has the constellations of symptoms described above with corroborating epidemiological evidence, Ebola virus infection can be suspected.

LABORATORY DIAGNOSIS

  • Early
    • Serology [Antigen‐capture enzyme‐linked immunosorbent assay (ELISA) testing, IgM ELISA]
    •  PCR
    • virus isolation 
  • Late
    • IgM and IgG antibodies.
  • Post
    • humus Immuno‐histochemistry testing,
    • Virus isolation
    • PCR

LABORATORY FINDINGS
  • Low white blood cell and platelet counts and elevated liver enzymes.
  • Treatment
  • There is no specific treatment for Ebola HF. Patients receive supportive therapy. This consists of balancing the patient’s fluids and electrolytes, blood pressure and treating them symptomatically and treating for any complicating infections.

PREVENTION

  • Suspected cases should be isolated from other patients
  • Inform MoH, Epidemiology Unit and RDHS immediately.
  • All hospital staff should be briefed on the nature of the disease and its mode of transmission.
  • Strict barrier nursing techniques should be implemented.
  • Particular emphasis should be placed on ensuring that invasive procedures such as placing of intravenous lines and handling of blood, secretions, catheters and suction devices are carried out under strict barrier nursing conditions.
  • Hospital staff should have individual gowns, gloves, masks, closed resistant shoes (e.g. boots) and goggles etc. Non‐disposable protective equipment must be reused only after they have been properly disinfected.
  • Perform hand hygiene before and after direct patient care
  • Infection may also spread through contact with soiled clothing or bed linen from a patient with Ebola. 
  • Protective clothing should be worn when handling soiled linen and soiled linen should be disinfected with an effective disinfectant (e.g. 1% Sodium Hypochlorite Solution) in addition to the normal cleaning procedures. Contaminated surfaces should be disinfected with an effective disinfectant (e.g. 1% Sodium Hypochlorite Solution).
  • Contacts Contact tracing and case finding interviews should be conducted outdoors whenever possible and a distance of more than one metre should be maintained between interviewer and interviewee. Protective equipment is not required if this distance is assured. Protective equipment is not required when interviewing asymptomatic individuals
  • Burial of the deceased Post‐mortem examination of HF patient remains should be limited to essential evaluations only Remains should be wrapped in sealed, leak‐ proof material and should be buried promptly. Only trained personnel should handle the human remain